Are there any data for second line nivolumab-ipilimumab in patients with metastatic NSCLC treated with either single agent pembrolizumab or chemotherapy + ICI as first line therapy?

Resistance to PD-(L)1 inhibitor based first line therapy and choice of subsequent treatment for patients with advanced NSCLC is an ongoing challenge. While addition of CTLA-4 inhibitor to PD-1 inhibitor has shown additive anti-tumor activity via complementary mechanisms of action, it is currently un...